Every once in a while, you meet someone who truly understands the hidden machinery behind an industry—someone who has seen how the system actually works, who knows its strengths and its flaws, and who dares to speak up about them.
That is how I would describe my guest, Hedley Rees.
With over forty years in biotech and pharmaceutical manufacturing, Hedley is not just a commentator; he is a practitioner who understands what it takes to build safe, reliable drug supply chains. From working at Bayer in Wales to leading supply chain operations for major biotech launches in the US, his experience bridges the technical, commercial, and ethical layers of drug development.
As I spoke with him, I realized that what he has been saying for years is both profoundly simple and deeply uncomfortable for the modern industry: we have forgotten how to make safe medicines.
The Forgotten Art of Drug Development
Hedley began by explaining how the process is supposed to work. A new compound doesn’t just appear in a vial ready for injection. It takes years—often more than a decade—to move from molecular design through animal safety testing, scaling up manufacturing, and clinical trials. Each step involves careful validation and documentation.
“It takes three years just to complete non-clinical testing before you go into humans,” he said, citing data from the US Government Accountability Office. “Then another seven years for the clinical trials. That’s ten years minimum, even with everything going smoothly.”
That’s why when I asked whether it was even possible to safely deliver a vaccine through Operation Warp Speed—compressing a decade into less than a year—his answer was immediate and unwavering.
“No. You’d have to skip safety testing altogether.”
What “Warp Speed” Really Meant
To meet political and public expectations in 2020, companies didn’t just accelerate timelines—they re-engineered the very rules of drug development. Phases of clinical trials were run in parallel instead of sequentially. Large-scale manufacturing began before final safety results were known.
Every scientist knows that scaling up a biologic changes its chemistry; every quality engineer knows that a frozen product can degrade unpredictably when thawed. Yet millions of doses were shipped to makeshift vaccine centres without the controlled protocols or qualified personnel required by good manufacturing practice.
In Hedley’s words, “The finishing part of the supply chain was people in car parks thawing drugs. That’s never been acceptable before.”
The Broken Chain of Vigilance
One of the most alarming insights from our conversation was about pharmacovigilance—the global system meant to detect adverse effects in real time. According to the law, responsibility for safety monitoring lies not with regulators but with the product license holder, the pharmaceutical company itself.
“They are required to detect serious adverse events within hours and act immediately,” Hedley explained. “The Yellow Card or VAERS systems are just backups. But during the rollout, the primary systems weren’t functioning.”
That single failure changes everything. Because if no one is tracking real-time safety at the source, then no one is truly accountable for harm.
Manufacturing Without Oversight
Through a Freedom of Information request, Hedley obtained the FDA inspection report for the Pfizer-BioNTech manufacturing site. It documented thirteen major observations: untrained staff, out-of-control processes, and contaminated equipment. Yet production continued, and billions of doses were distributed worldwide.
When I asked him how such a thing could happen in an industry that prided itself on quality control, his answer was stark:
“The regulators have abandoned the standards that defined the last forty years of safe manufacturing.”
The Industry That Lost Its Nerve
Perhaps the most sobering part of our conversation was not about science but about silence. Hedley spoke quietly when I asked why more insiders weren’t speaking out.
“There’s fear,” he said. “People are afraid to remember how we used to make drugs safely. They just keep their heads down.”
That fear, I believe, is now the greatest danger of all. Because if those who know the truth remain silent, the entire reputation of the pharmaceutical industry may collapse when the consequences of these shortcuts fully emerge.
Can the System Recover?
When I pressed him on how to move forward, Hedley’s answer wasn’t optimistic but it was clear:
We need to stop rushing new gene-based therapies until we truly understand them. We need to restore proper safety testing, and we need doctors back in the development process—not just scientists chasing molecular targets.
He warned that the current race toward mRNA, CAR-T, and CRISPR technologies risks repeating the same mistakes, this time with even higher stakes.
“These therapies carry black-box warnings for neurological toxicity and secondary cancers. Yet they’re still being pushed to market.”
A Final Reflection
Listening to Hedley Rees, I was struck by a deep irony. The system built to protect public health has, in the pursuit of speed and profit, begun to undermine it. The same structures of oversight and accountability that once guaranteed safety have been quietly set aside.
As a clinician, I cannot ignore this. When the next crisis comes, we cannot afford to build on broken foundations. Transparency, integrity, and the courage to speak out must once again define how medicine is made.
Timecodes
00:00 – Introduction: The Whistleblower in Pharma
I introduce Hedley Rees, a veteran of the biotech and pharmaceutical industry, and explain why his insights matter. Hedley shares his 40-year journey—from Bayer to leading drug launches and writing books on supply-chain integrity.
03:30 – How Drug Development Really Works
He explains what happens behind the scenes before a drug reaches patients—and why clinicians should be part of that process.
05:40 – The Problem with the “One Miracle Drug” Mindset
We discuss why medicine needs toolboxes, not single-shot solutions, and how this narrow view harms innovation.
07:10 – Doctors and the Missing Knowledge Gap
Hedley argues that doctors need to understand supply-chain and manufacturing basics to reclaim influence in drug development.
08:05 – Could Operation Warp Speed Ever Be Safe?
We explore whether it was even possible to produce a vaccine safely in under a year.
10:25 – Why Vaccines Are Harder Than Drugs
Hedley contrasts small-molecule chemistry with biologics and reveals the hidden risks of freezing and thawing fragile products.
13:00 – What Shortcuts Were Taken
Running all three trial phases in parallel—and skipping safety testing—comes under scrutiny.
16:00 – Can You Fix Safety Testing After the Fact?
We unpack why once untested batches go into people, it’s impossible to go back.
20:00 – The Myth of “Real-World Testing”
If billions received it safely, is everything fine? Hedley explains why absence of data isn’t proof of safety.
21:00 – Inside the FDA Inspection: What They Found
Hedley reveals details from a Freedom of Information report on the first Pfizer-BioNTech plant and its shocking deficiencies.
24:30 – Who Was Responsible for Reporting Adverse Events?
We discuss how pharmacovigilance was bypassed and why yellow-card systems were never meant to carry that load.
31:00 – Lipid Nanoparticles and the Risk of Adduction
A deep dive into the chemistry concerns raised by insiders—and why certain safety tests were never done.
37:00 – Thawing Vaccines in Car Parks
Hedley explains how improvised logistics and untrained staff created uncontrolled variability across vaccination sites.
44:00 – Lessons from Heparin: When the Supply Chain Kills
He recalls a 2008 contamination tragedy that reshaped drug-safety law—then warns it could happen again.
50:00 – Can the Industry Regain Trust?
Final reflections on regulation, accountability, and why the next generation of therapies must not repeat these mistakes.
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
